Inflammation in coronary artery diseases

Chinese Medical Journal

Volumn 124, Issue 21, 2011, Pages 3568-3575

  Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atherosclerosis; Coronary artery disease; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; L SELECTIN; LIPOPROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PACLITAXEL; RAPAMYCIN; STATIN;

ARTERY INTIMA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE COURSE; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; MICROCIRCULATION; MICROVASCULATURE; NOCICEPTION; PATHOPHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; SILENT MYOCARDIAL ISCHEMIA; SYNDROME X; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VARIANT ANGINA PECTORIS;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION;

EID: 82255173973     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.21.024     Document Type: Article

References (65)

1. Turakhia M, Tseng ZH. Sudden cardiac death: epidemiology, mechanisms, and therapy. Curr Probl Cardiol 2007; 32: 501-546.
2. Bachar GN, Atar E, Fuchs S, Dror D, Komowski P. Prevalence and clinical predictors of atherosclerotic coronary artery disease in asymptomatic patients undergoing coronary multidetector computed tomography. Coron Artery Dis 2007; 18: 353-360.
3. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-460S.
4. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10: 63-71.
5. Li JJ. Inflammation: an important mechanism for different clinical entities of coronary artery diseases. Chin Med J 2005; 118: 1817-1826.
6. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 2004; 4: 166-170.
7. Li JJ, Li YS, Hui RT, Yang YJ, Chen JL, Gao RL. Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin-10 in patients with unstable angina. Heart 2006; 92: 529-530.
8. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-460S.
9. Ross R. Atheroslcerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Libby P, Ridlker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
11. Tousoulis D, Charadida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J 2008; 84: 368-371.
12. Sima AV, Stancu CS, Simionescu M. Vascular endothelium in atherosclerosis. Cell Tissue Res 2009; 335: 191-203.
13. Behrendt D, Ganz P. Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
14. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009; 23: 31-40.
15. Shah PK. Molecular mechanisms of plaque instability. Curr Opin Lipidol 2007; 18: 492-499.
16. Li JJ, Jiang H, Huang CX, Fang CH, Tang QZ, Xia H, et al. Elevated C-reactive protein of plasma in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology 2002; 53: 265-272.
17. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
18. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
19. Li JJ, Wang HR, Huang CX, Xue JL, Li GS. Enhanced response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta 2004; 352: 127-133.
20. Li JJ, Fang CH, Cheng MZ, Chen X, Lee SW. Activation of nuclear factor-κB and correlation with elevated plasma C-reactive protein in patients with unstable angina. Heart Lung Circ 2004; 13: 173-178.
21. Hearse DJ, Maxwell L, Saldanha C, Gavin JB. The myocardial vasculature during ischemia and reperfusion: a target for injury and protection. J Mol Cell Cardiol 1993; 25: 759-800.
22. Hansen PR. Inflammation alterations in the myocardial microcirculation. J Mol Cell Cardiol 1998; 30: 2555-2559.
23. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872-1885.
24. Li JJ, Li YS, Zhang Y, Gao Z, Li Z, Qian HY. Inflammation: a possible pathogenic link to cardiac syndrome X. Med Hypotheses 2006; 66: 527-530.
25. Li JJ, Zhu CG, Nan JL, Li J, Li ZC, Zeng HS, et al. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine 2007; 40: 172-176.
26. Lanza GA, Sestito A, Cammarota G, Grillo RL, Vecile E, Cianci R, et al. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol 2004; 94: 40-44.
27. Li JJ, Wang Y, Nie SP, Li Q, Li YS, Huang Y, et al. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X. Int J Cardiol 2007; 122: 82-84.
28. Caligiuri G, Liuzzo G, Biasucci ML, Maseri A. Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol 1998; 97: 2000-2002.
29. Li JJ. Silent myocardial ischemia may be related to inflammatory response. Med Hypotheses 2004; 62: 252-256.
30. Mazzone A, Cusa C, Mazzuccheli I, Vezzoli M, Ottini E, Pacifici R, et al. Increased production of inflammatory cytokines in patients with silent myocardial ischemia. J Am Coll Cardiol 2001; 38: 1895-1901.
31. Li JJ, Nie SP, Xu B, Guo YL, Gao Z, Zheng X. Inflammation in variant angina: is there any evidence? Med Hypotheses 2007; 68: 635-640.
32. Lewis JR, Kisilevsky R, Armstrong PW. Prinzmetal's angina, normal coronary arteries and pericarditis. Can Med Assoc J 1978; 119: 36-39.
33. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ, Virmani R. Increased adventitial mast cells in a patients with coronary spasm. N Engl J Med 1985; 313: 1138-1141.
34. Li JJ, Zhang YP, Yang P, Zeng HS, Qin XW, Zhang CY, et al. Increased peripheral circulating inflammatory cells and inflammatory markers in patients with variant angina. Coron Artery Dis 2008; 19: 293-297.
35. Kocaman SA, Tacoy G, Sahinarslan A, Cengel A. Relationship between total and differential leukocyte counts and isolated coronary artery ectasia. Coron Artery Dis 2008; 19: 307-310.
36. Li JJ. Is any link between inflammation and coronary artery ectasia? Med Hypotheses 2007; 69: 679-683.
37. Li JJ, He JG, Nan JL, He ZX, Zhu CG, Li J. Is systemic inflammation responsible for coronary artery ectasia? Int J Cardiol 2008; 130: e69-e70.
38. Schoenhagen P, Ziada KM, Vince G, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol 2001; 38: 297-306.
39. Li JJ, Nie SP, Qin XW, Zeng HS, Zhang CY. Chronic inflammatory status in patients with coronary artery ectasia. Cytokine 2009; 46: 61-64.
40. Finkelsein A, Michowitz Y, Abashidze A, Miller H, Keren G, George J. Temporal association between circulating proteolytic, inflammatory and neurohormonal markers in patients with coronary ectasia. Atherosclerosis 2005; 179: 353-359.
41. Turhan H, Erbay AR, Yasar AS, Balci M, Bicer A, Yetkin E. Comparison of C-reactive protein levels in patients with coronary artery ectasia versus patients with obstructive coronary artery disease. Am J Cardiol 2004; 94: 1303-1306.
42. Li JJ, Zhu CG, Yu B, Liu YX, Yu MY. The role of inflammation in coronary artery calcification. Ageing Res Rev 2007; 6: 263-270.
43. Mazzini MJ, Schulze PC. Proatherogenic pathways leading to vascular calcification. Eur J Radiol 2006; 57: 384-389.
44. Kume T, Okura H, Kawamoto T, Akasaka T, Toyota E, Neishi Y, et al. Assessment of the histological characteristics of coronary arterial plaque with severe calcification. Circ J 2007; 71: 643-647.
45. Stay HC. The sequence of cell and matrix changes in atheroscleorotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990; 11: 3-9.
46. Ehara S, Yoshiyama M. Clinical implication of coronary calcification. Clin calcium 2007; 17: 325-331.
47. Wang TJ, Larson MG, Levy D, Benjamin EJ, Kupka MJ, Manning WJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 2002; 106: 1189-1191.
48. Erbel R, Mohlenkamp S, Lehmann N, Schmermund A, Moebus S, Stang A, et al. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. Atherosclerosis 2007; 197: 662-672.
49. Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Fernandes Canzianis ME. Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. Nephron Clin Pract 2006; 104: C33-C40.
50. Bennett MR. In-stent restenosis: pathology and implications for the development of drug eluting stent. Heart 2003; 89: 218-214.
51. Bennett MR. In-stent restenosis: pathology and implications for the development of drug eluting stent. Heart 2003; 89: 218-214.
52. Li JJ, Li Z, Li J. Is inflammation a contributor for in-stent restenosis? Med Hypotheses 2007; 68: 945-951.
53. Li JJ, Fang CH, Jiang H, Huang CX. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal artery stenosis. Clin Chim Acta 2004; 350: 115-121.
54. Versaci F, Gaspardone G. Prevention of restenosis after stenting: the emerging role of inflammation. Coron Artery Dis 2004; 15: 307-311.
55. Li JJ, Fang CH, Jaing H, Huang CX. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology 2004; 55: 479-484.
56. Li JJ. Inflammatory response, drug-eluting stent and restenosis. Chin Med J 2008; 121: 566-572.
57. Li JJ, Qin XW, Yang XC, Li ZC, Zeng HS, Xu B, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs. bare metal stent implantation in native coronary lesions. Clin Chim Acta 2008; 396: 38-42.
58. Li JJ, Zhang YP, Wang C, Gao LJ, Qin XW, Xu B, et al. Impact of direct sirolimus-eluting stent implantation on the early systemic inflammatory response compared with complementary stent implantation. Coron Artery Dis 2009; 20: 65-70.
59. Li JJ, Yan HB, Xiang XP, Qin XW, Zhang CY. Comparison of changes in early inflammatory markers between sirolimus-and paclitaxel-eluting stent implantation. Cardiovasc Drug Ther 2009; 23: 137-143.
60. Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-824.
61. Aggarwal A, Blum A, Schender DJ, Sobel BE, Dauerman HL. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 2004; 15: 471-475.
62. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, et al. Interleukin-6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000; 84: 83-87.
63. Koster R, Vieluf D, Kiehn M, Sommerauer M, Kahler J, Baldus S, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356: 1895-1897.
64. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004; 62: 499-506.
65. Li JJ, Gao RL. Maximizing benefit of drug-eluting stent by direct coronary stenting because of further reduction of inflammatory response. Chin Med J 2009; 122: 732-735.